Antibody-drug conjugates are set to take make their presence felt at the upcoming American Society for Clinical Oncology (ASCO) congress in Chicago, pre-publication of the abstracts suggests.
Interest in the antibody-drug conjugate (ADC) field has been fueled by the runaway success of AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s Enhertu (trastuzumab deruxtecan) and Pfizer Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?